Tandem Diabetes Care (TNDM) Operating Expenses (2013 - 2026)

Tandem Diabetes Care has reported Operating Expenses for 14 years, with the latest figure at $154.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 35.55% year-over-year to $154.2 million; the trailing twelve-month figure through Mar 2026 stood at $648.2 million (down 6.28% YoY), and the FY2025 full-year result was $733.3 million, up 24.56% from the prior year.
• Operating Expenses for Q1 2026 stood at $154.2 million, down from $159.2 million in the prior quarter.
• The five-year high for Operating Expenses was $239.3 million in Q1 2025, with the low at $106.4 million in Q1 2022.
• Historically, Operating Expenses has averaged $151.9 million across 5 years, with a median of $150.7 million in 2024.
• Annual changes were most pronounced in 2023 — Operating Expenses soared 97.99% — and 2026, when it sank 35.55%.
• Tandem Diabetes Care's Operating Expenses stood at $133.3 million in 2022, then slipped by 3.71% to $128.4 million in 2023, then grew by 23.12% to $158.0 million in 2024, then gained by 0.72% to $159.2 million in 2025, then decreased by 3.11% to $154.2 million in 2026.
• The last three Operating Expenses figures came in at $154.2 million (Q1 2026), $159.2 million (Q4 2025), and $157.2 million (Q3 2025), per Business Quant data.